T-Cell Non-Hodgkin Lymphoma Clinical Trials

26 clinical trials for T-Cell Non-Hodgkin Lymphoma across international registries, including 5 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• CD45BE-HSPC + CART-45 Cells — RECRUITING · PHASE1
• CD5-deleted Chimeric Antigen Receptor Cells (Senza5 CART5) for T Cell Non-Hodgkin Lymphoma (NHL) — RECRUITING · PHASE1
• CD5 CAR T-Cell Therapy for r/r T-cell Lymphomas — RECRUITING · PHASE1
• CD7 CAR T-Cell Therapy for r/r T-cell Lymphomas — RECRUITING · PHASE1
• Allogeneic Stem Cell Transplantation in Relapsed/Refractory T-, NK/T-cell Lymphomas — RECRUITING · PHASE2
• Dose-Escalation and Dose-Expansion Study to Evaluate the Safety and Tolerability of Anti-CD7 Allogeneic CAR T-Cells (WU-CART-007) in Patients With CD7+ Hematologic Malignancies — SUSPENDED · PHASE1
• Phase I/II Study Evaluating AUTO4 in Patients With T Cell Receptor Beta Constant (TRBC)1 Positive T Cell Lymphoma — TERMINATED · PHASE1
• A Phase 2 Multicenter Study of High Dose Chemotherapy With Autologous Stem Cell Transplant Followed by Maintenance Therapy With Romidepsin for the Treatment of T Cell Non-Hodgkin Lymphoma — COMPLETED · PHASE2
• Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Blood Cancer — TERMINATED · PHASE2
• Romidepsin and Parsaclisib for the Treatment of Relapsed or Refractory T-Cell Lymphomas — COMPLETED · PHASE1
• Lenalidomide and Ipilimumab After Stem Cell Transplant in Treating Patients With Hematologic or Lymphoid Malignancies — COMPLETED · PHASE2
• MargheRITA (Remote Intelligence for Therapeutic Adherence) — COMPLETED · NA
• Phase I/Ib Study of Nivolumab & Veliparib in Patients With Advanced Solid Tumors & Lymphoma — COMPLETED · PHASE1
• A Study of Zilovertamab Vedotin (MK-2140) (VLS-101) in Participants With Hematologic Malignancies (MK-2140-001) — COMPLETED · PHASE1
• CHOEP + High Dose Therapy + Auto SCT for T-Cell Lymphoma — TERMINATED · PHASE2
• Anti-CD7 CAR-Engineered T Cells for T Lymphoid Malignancies Malignancies — OTHER · PHASE1
• Safety and Efficacy of ThisCART7 in Patients With Refractory or Relapsed T Cell Malignancies — OTHER · PHASE1
• Study to Assess Safety, Tolerability, Pharmacokinetics and Antitumor Activity of AZD4573 in Relapsed/Refractory Haematological Malignancies — COMPLETED · PHASE1
• CD8+ Memory T-Cells as Consolidative Therapy After Donor Non-myeloablative Hematopoietic Cell Transplant in Treating Patients With Leukemia or Lymphoma — COMPLETED · PHASE2
• Non-gene Edited Anti-CD7 CAR T Cells for Relapsed/Refractory T Cell Malignances — OTHER · PHASE1
• Anti-CD5 CAR T Cells for Relapsed/Refractory T Cell Malignancies — OTHER · PHASE1
• Bortezomib and Vorinostat as Maintenance Therapy After Autologous Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma — COMPLETED · PHASE2
• Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer — COMPLETED · PHASE2
• Management of Platelet Transfusion Therapy in Patients With Blood Cancer or Treatment-Induced Thrombocytopenia — TERMINATED · PHASE2
• Fludarabine, Bendamustine, and Rituximab in Treating Participants With Lymphoid Cancers Undergoing Stem Cell Transplant — COMPLETED · PHASE1
• Gleevec in Relapsed/Refractory T Cell Non-Hodgkin's Lymphoma — COMPLETED · PHASE2

Refine this search